Brain tumours are the most common solid tumours in children. Even a non-cancerous tumour can cause serious harm if it presses on parts of the brain that control movement, vision or other essential functions. Survival varies widely by tumour type.
Treatment decisions are especially difficult for the very young children. Radiotherapy can affect the developing brain, so doctors may delay or avoid it when possible. Some childhood brain cancers also have biological features that differ from those seen in adults, which can make it harder to find suitable drugs among existing treatments.
Getting a drug to the tumour is a challenge in its own right. The blood–brain barrier controls what passes from the bloodstream into the brain. In some childhood brain tumours, much of that barrier remains intact. A compound may kill tumour cells in the lab and still fail to reach them in the brain at a high enough concentration to work.
Brain cancer is a priority for THINK (Therapeutic Innovations for Kids), a drug discovery initiative at Children’s Cancer Institute that starts with the biology of childhood cancers. Its technology allows researchers to test many compounds quickly against cancer cells, rule out those that show little promise and focus on the ones worth developing further. For brain cancers, that means asking early whether a promising compound can both act on the tumour and reach it. The aim is to shorten the time it takes to identify drug candidates that can move towards clinical trials for children.